High Margins & Profitability TurnaroundSustained gross margin of 64.8% and a 25.7% net margin indicate durable pricing power and efficient cost structure in reagent manufacturing. These margins provide cash to fund R&D, product quality, and incremental margin expansion, insulating profits from moderate volume swings.

Low Leverage, Strong CapitalizationA debt-to-equity of 0.13 and 82% equity ratio reduce refinancing and solvency risk, enabling the company to fund growth initiatives, absorb R&D cycles, and pursue selective M&A from a position of financial strength without stressing cash flow.

Improving Cash GenerationAn OCF-to-net-income ratio near 0.74 shows solid cash conversion, supporting repeat purchases of consumables and contract projects. Reliable operating cash flow enhances financial flexibility to invest in product development and absorb short-term demand variability.

Bears Say

Modest Revenue Growth RateRevenue growth around 8.8% is steady but modest for the life-science reagents market. Without faster top-line expansion, the company may struggle to scale market share or fully leverage fixed costs, making sustained margin and cash improvements harder over the medium term.

Narrow Product/service FocusConcentration on immunoassay reagents, antibodies and contract assay services limits diversification. Technological shifts, new assay platforms, or reduced research funding in key segments could disproportionately impact revenues and require time-consuming product pivots.

Limited Disclosed Strategic InitiativesThe absence of recent announced partnerships, product launches, or strategic M&A suggests limited externally disclosed catalysts to accelerate growth. Reliance on organic expansion may restrict scaling speed and leave the company vulnerable to more proactive competitors.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥356.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥13.96B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 73 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on Feb 12, 2026. The company reported ¥11.44 earnings per share for the quarter, beating the consensus estimate of N/A by ¥11.44.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥6 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥11.44 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.396%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.